Signal52

FOLD

Featured Pick

Amicus Therapeutics, Inc.

Real picks. Real tracking. We bet on one stock daily and show you exactly how it plays out.

AI Confidence Score
90
Entry Price
$14.49
Current Price
$14.49
Total Return
+0.00%
vs SPY
+0.00%
As of Close 2026-04-24

Executive Summary

Amicus Therapeutics (FOLD) has just secured final regulatory clearance from the French Ministry of Economics and Finance, removing the last major hurdle for its $4.8 billion acquisition by BioMarin. This definitive M&A catalyst arrives in a highly supportive RISK_ON market regime where stable volatility and strong breadth reward aggressive positioning. With the final approval serving as the exact fundamental trigger, FOLD is perfectly positioned to transition from a quiet accumulation phase into a full momentum breakout.

Technical Context

Setup
The stock is consolidating perfectly at its 52-week high (+0.0%) on surging 1.5x relative volume, triggering rare ALPHA_MALE and QUIET_STORM signals that confirm heavy institutional demand.
Invalidation (Stop)
This momentum breakout setup is invalidated if the stock loses its structural support and closes below $14.41.

Runner-ups

CVLGStrong technical momentum and revenue beat, but EPS miss and 25% recent run-up suggest potential exhaustion.
WAFDExcellent technical score (18.0) and breakout setup, but lacks a fresh fundamental catalyst to drive the next leg higher.

Recent Performance History

56 Total Picks • 53% Win Rate (7d)
DateTickerEntryLastGain/Loss7d30d60d
2026-04-23WAFD$35.42$35.20-0.62%N/AN/AN/A
2026-04-22ASND$231.05$229.27-0.77%N/AN/AN/A
2026-04-21DBRG$15.61$15.60-0.06%N/AN/AN/A
2026-04-20WAFD$35.20$35.20+0.00%N/AN/AN/A
2026-04-17WAFD$35.24$35.20-0.11%-0.11%N/AN/A
2026-04-16WABC$53.71$55.02+2.44%+1.75%N/AN/A
2026-04-15ASND$241.71$229.27-5.15%-4.41%N/AN/A
2026-04-13ASND$248.55$229.27-7.76%-1.28%N/AN/A
2026-04-10DBRG$15.55$15.60+0.32%+0.26%N/AN/A
2026-04-09PKBK$29.80$30.02+0.74%-1.58%N/AN/A
Schema v1.0 | Pipeline v1.2.0